DV
Dividend Vision

HUMA — Humacyte Inc

Humacyte Inc (HUMA)

Total return is -93.7% over the past 5.7 years, 223.1 points behind SPY at 129.4%. Its deepest 1-year drawdown was 77.8%.

Humacyte Inc. is a biomedical company developing and manufacturing human acellular vessels (HAVs)—off-the-shelf, implantable tissues engineered using its proprietary technology platform—for vascular repair, reconstruction, and replacement across multiple therapeutic areas including arteriovenous access, peripheral arterial disease, and coronary artery bypass grafting. The company does not currently distribute dividends. Humacyte appeals primarily to growth-oriented investors seeking exposure to regenerative medicine and bioengineering rather than income-focused strategies.

HUMA key facts

Asset type
Stock
Asset class
Equity
Inception date
12/01/2020
Last close
$0.60
Market cap
$179,228,464
Average volume
33018600.0
Beta
2.517
Payout ratio
0.0
Forward P/E
35.8423
EPS
$-0.63